Clinical Trial Update: Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC. [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating envafolimab in combination with trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Envafolimab (envafolimab)
• trifluridine/tipiracil (trifluridine/tipiracil)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: UNKNOWN